Fennec Pharmaceuticals In...

NASDAQ: FENC · Real-Time Price · USD
8.39
-0.14 (-1.64%)
At close: Aug 15, 2025, 3:59 PM
8.36
-0.36%
After-hours: Aug 15, 2025, 04:10 PM EDT

Fennec Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
30.91M 47.54M 49.35M 48.89M 44.95M 21.25M 13.05M 6.54M 3.21M 1.53M n/a n/a n/a n/a 170K 170K 170K
Cost of Revenue
3.01M 3.18M 3.2M 2.17M 1.71M 1.26M 660K 389.4K 249.34K 161.42K 75.42K 15.02K 7.09K n/a n/a n/a n/a
Gross Profit
27.91M 44.35M 46.15M 46.72M 43.24M 19.99M 12.39M 6.15M 2.96M 1.37M -75.42K -15.02K -7.09K n/a 170K 170K 170K
Operating Income
-11.98M 2.57M 1.68M 5.87M 6.24M -12.77M -17.09M -23.97M -24.31M -22.59M -20.66M -16.93M -15.85M -17.22M -16.36M -18.05M -18.97M
Interest Income
1.7M 1.66M 1.4M 984K 530.52K 442.52K 480.52K 402.52K 294.92K 194.92K 54.92K 43.83K 46.91K 53.91K 53.91K 63K 68K
Pretax Income
-14.07M -71K -1.13M 2.73M 2.84M -16.05M -20.22M -26.44M -26.07M -23.71M -21.27M -17.34M -16.27M -17.34M -16.16M -18.21M -19.13M
Net Income
-14.44M -436K -1.13M 2.73M 2.84M -16.05M -21.16M -27.38M -26.99M -24.73M -21.36M -17.46M -16.4M -17.35M -16.16M -18.17M -19.02M
Selling & General & Admin
39.49M 41.48M 44.17M 40.64M 36.94M 32.71M 29.34M 29.2M 25.25M 20.51M 16.72M 12.6M 11.84M 12.24M 10.85M 12.41M 13.02M
Research & Development
398K 307K 289K 204K 55K 56K 141K 975K 2.1M 3.53M 3.94M 4.33M 4M 4.98M 5.68M 5.81M 6.13M
Other Expenses
n/a n/a -72K -72K -72K -72K 86K 86K 86K 86K 9K 8K 8K n/a -14K -21K -8K
Operating Expenses
39.89M 41.79M 44.46M 40.85M 37M 32.76M 29.57M 30.26M 27.43M 24.12M 20.66M 16.93M 15.85M 17.22M 16.53M 18.22M 19.14M
Interest Expense
3.66M 4.09M 4.04M 3.87M 3.71M 3.48M 3.38M 2.64M 1.79M 1.05M 295.51K 231.14K 183.63K 129.63K 67.63K 13K 4K
Selling & Marketing Expenses
16.16M 18.43M 18.35M 17.13M 14.8M 12.12M 11.04M 7.66M 5.32M 2.79M n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
42.9M 44.97M 47.66M 43.02M 38.71M 34.02M 30.14M 30.51M 27.52M 24.12M 20.66M 16.93M 15.85M 17.22M 16.53M 18.22M 19.14M
Income Tax Expense
n/a n/a n/a n/a n/a n/a 935K 1.01M 992K 1.08M 211K 186K 197K 89K 416K 348K 334K
Shares Outstanding (Basic)
27.58M 27.46M 27.37M 27.3M 27.05M 26.83M 26.46M 26.46M 26.56M 26.36M 26.09M 26.05M 26.02M 26.01M 26.01M 26M 26M
Shares Outstanding (Diluted)
27.58M 27.46M 27.37M 27.3M 31.09M 26.83M 26.46M 26.46M 26.56M 26.36M 26.11M 26.05M 26.02M 26.01M 26.01M 26M 26M
EPS (Basic)
-0.51 n/a -0.04 0.10 0.09 -0.67 -0.87 -1.11 -1.09 -0.95 -0.82 -0.67 -0.63 -0.66 -0.63 -0.71 -0.77
EPS (Diluted)
-0.51 -0.06 -0.1 0.04 0.03 -0.67 -0.87 -1.11 -1.09 -0.95 -0.82 -0.67 -0.63 -0.66 -0.63 -0.71 -0.77
EBITDA
-10.34M 4.8M 3.73M 7.47M 7.34M -12.44M -16.85M -23.81M -24.21M -22.66M -20.91M -17.14M -16.12M -17.22M -16.2M -18.27M -19.12M
EBIT
-10.38M 4.05M 2.89M 6.61M 6.47M -12.65M -17M -23.96M -24.35M -22.74M -20.99M -17.15M -16.13M -17.22M -16.16M -18.23M -19.09M
Depreciation & Amortization
103K 800K 844K 891K 813K 142K 241K 229.4K 289.33K 244.34K 67.33K 14.93K 3.93M 8.84M 8.45M 8.8M 4.91M